Baker Bros. Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Baker Bros. Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-310,354	Closed	-$5.91M	–	113
2018 Q2	$5.91M	Sell	310,354 -290,000	-48%	-$4.85M	0.04%	67
2018 Q1	$10.1M	Buy	600,354 +176,470	+42%	+$2.95M	0.09%	58
2017 Q4	$6.44M	Hold	423,884	–	–	0.06%	70
2017 Q3	$7.59M	Buy	+423,884	New	+$7.09M	0.06%	64
2015 Q3	–	Sell	-409,881	Closed	-$5.2M	–	135
2015 Q2	$5.2M	Sell	409,881 -1,340,349	-77%	-$14.5M	0.05%	78
2015 Q1	$16.3M	Sell	1,750,230 -2,721,923	-61%	-$30.8M	0.14%	48
2014 Q4	$64M	Buy	4,472,153 +100,000	+2%	+$1.18M	0.65%	23
2014 Q3	$45.4M	Hold	4,372,153	–	–	0.57%	23
2014 Q2	$70.7M	Sell	4,372,153 -73,543	-2%	-$980K	0.87%	18
2014 Q1	$72.2M	Sell	4,445,696 -345,483	-7%	-$4.91M	0.92%	19
2013 Q4	$59.5M	Hold	4,791,179	–	–	0.84%	17
2013 Q3	$52.5M	Buy	4,791,179 +825,000	+21%	+$8.81M	0.75%	22
2013 Q2	$32M	Buy	+3,966,179	New	+$26.7M	0.63%	23

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baker Bros. Advisors's VNDA Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q3 2018, closing a stake of 310,354 shares — an estimated $5.91M sold.

Baker Bros. Advisors first reported a position in VNDA in Q2 2013 and held it in 13 quarters. The position peaked at $72.2M in Q1 2014. 160 funds tracked by Wall St. Rank hold VNDA as of Q3 2018.

Baker Bros. Advisors reported no remaining Vanda Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Baker Bros. Advisors sold 310,354 Vanda Pharmaceuticals shares in Q3 2018, an estimated $5.91M.
Baker Bros. Advisors first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Baker Bros. Advisors's Vanda Pharmaceuticals position peaked at $72.2M in Q1 2014.
160 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.